Tango Therapeutics director Aaron Davis resigns; John Ketchum appointed to board

Tango Therapeutics, Inc.

Aaron Davis resigned from board effective Aug 28, 2023; no disagreement with management.
John Ketchum appointed as Class III director effective Aug 29, 2023; will stand for election at 2024 annual meeting.
Ketchum receives option for 60,000 shares at $7.19, RSU for 10,000 shares, and $40k annual retainer.
Ketchum deemed independent under Nasdaq rules; no committee assignments yet.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Aaron Davis

Member of the Board of Directors, Class III director

TNGX · Tango Therapeutics, Inc.

Effective: 2023-08-28
Successor: John Ketchum
Filed: August 30, 2023, 7:59 PM ET

On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.

Appointed

John Ketchum

Director (Class III)

TNGX · Tango Therapeutics, Inc.

Effective: 2023-08-29
Filed: August 30, 2023, 7:59 PM ET

Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Davis resigned as Member of the Board of Directors, Class III director at Tango Therapeutics, Inc..

Action: resigned
Role: Member of the Board of Directors, Class III director

Exact text from the filing

On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Ketchum was appointed as Director (Class III) at Tango Therapeutics, Inc..

Action: appointed
Role: Director (Class III)

Exact text from the filing

Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.

View on SEC.gov

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-224253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.